Alx Oncology Holdings Inc (ALXO) Stock Price, Quote & News

Company Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 466 7125

Website: www.alxoncology.com

Address:

323 Allerton Avenue, South San Francisco, United States

Arthur_PL Oct. 24 at 2:15 PM

$ALXO so... we got it!

0 · Reply

the_cha_rtist Oct. 24 at 1:28 AM

$ALXO technically speaking $7 is the target

1 · Reply

Thestocktraderhubzee Oct. 23 at 5:06 PM

$ALXO ALX Oncology Presents Preclinical Data And Trial Design For Ongoing Phase 1 Clinical Trial For ADC Candidate, ALX2004, In Two Poster Presentations At 2025 AACR-NCI-EORTC Conference

0 · Reply

S2K_TP Oct. 23 at 4:50 PM

$ALXO 52%⬆️ 2 break on watch next 🚨

0 · Reply

Groin Oct. 23 at 3:44 PM

$ALXO been waiting too long for this cup

1 · Reply

Groin Oct. 23 at 3:21 PM

$ALXO We're back baby !

0 · Reply

jjrrjjrr Oct. 23 at 3:16 PM

$ALXO 🤫🤫

0 · Reply

StarLord13 Oct. 20 at 4:32 PM

$ALXO Need to break out of this downward channel.

0 · Reply

StarLord13 Oct. 16 at 8:06 PM

$ALXO This held up quite well considering where the rest of the market landed today.

1 · Reply

MakingMoneyHere Oct. 16 at 4:06 PM

$ALXO We need bulls here 😤

0 · Reply

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

Oct 3, 2025, 9:05 AM EDT - 22 days ago

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 12, 2025, 8:30 AM EDT - 6 weeks ago

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

Aug 29, 2025, 12:00 PM EDT - 2 months ago

ALX Oncology to Participate in Upcoming Investor Conferences in September

Aug 19, 2025, 8:00 AM EDT - 2 months ago

ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

Aug 12, 2025, 9:45 PM EDT - 2 months ago

ALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 2 months ago

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 5, 2025, 8:00 AM EDT - 2 months ago

ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025

May 30, 2025, 8:00 AM EDT - 5 months ago

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

May 20, 2025, 8:00 AM EDT - 5 months ago

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

May 13, 2025, 8:00 AM EDT - 5 months ago

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

May 8, 2025, 8:30 AM EDT - 6 months ago

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 2, 2025, 8:00 AM EDT - 6 months ago

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 25, 2025, 1:10 PM EDT - 6 months ago

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

Apr 25, 2025, 9:00 AM EDT - 6 months ago

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

Mar 6, 2025, 4:01 PM EST - 8 months ago

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 5, 2025, 8:00 AM EST - 8 months ago

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

Feb 27, 2025, 8:00 AM EST - 8 months ago

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 18, 2025, 8:00 AM EST - 8 months ago

ALX Oncology to Host Virtual R&D Day on March 5, 2025

Jan 23, 2025, 8:00 AM EST - 9 months ago

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

Jan 22, 2025, 4:01 PM EST - 9 months ago

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

Jan 21, 2025, 5:00 PM EST - 9 months ago

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

Dec 18, 2024, 8:00 AM EST - 11 months ago

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

Nov 14, 2024, 8:00 AM EST - 1 year ago

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

Nov 7, 2024, 4:00 PM EST - 1 year ago

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 1, 2024, 5:30 PM EDT - 1 year ago

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

Sep 11, 2024, 10:36 PM EDT - 1 year ago

ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

Aug 6, 2024, 4:01 PM EDT - 1 year ago

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

Jul 31, 2024, 4:01 PM EDT - 1 year ago

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

Jul 31, 2024, 5:30 AM EDT - 1 year ago

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Jun 27, 2024, 4:13 AM EDT - 1 year ago

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

Jun 2, 2024, 10:00 AM EDT - 1 year ago

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

May 29, 2024, 9:00 AM EDT - 1 year ago

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

May 9, 2024, 4:00 PM EDT - 1 year ago

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 9:00 AM EDT - 1 year ago

ALX Oncology Appoints Allison Dillon as Chief Business Officer

Apr 24, 2024, 10:00 AM EDT - 1 year ago

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

$ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)$

Apr 9, 2024, 5:30 PM EDT - 1 year ago

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

Mar 7, 2024, 4:03 PM EST - 1 year ago

ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 5, 2024, 4:30 PM EST - 1 year ago

ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting

Dec 8, 2023, 8:30 AM EST - 2 years ago

ALX Oncology shares jump 9% after Jefferies upgrade

Nov 13, 2023, 4:05 PM EST - 2 years ago

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 10, 2023, 4:05 PM EDT - 2 years ago

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 9, 2023, 12:38 AM EDT - 2 years ago

ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept

Oct 5, 2023, 8:00 AM EDT - 2 years ago

ALX Oncology Announces Pricing of Public Offering

Oct 4, 2023, 4:10 PM EDT - 2 years ago

ALX Oncology Announces Proposed Public Offering

Oct 3, 2023, 6:00 AM EDT - 2 years ago

ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Oct 2, 2023, 4:05 PM EDT - 2 years ago

ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Sep 6, 2023, 8:00 AM EDT - 2 years ago

ALX Oncology Realigns Executive Leadership Team

Aug 31, 2023, 7:00 AM EDT - 2 years ago

ALX Oncology Announces September Investor Conference Participation

Aug 10, 2023, 4:01 PM EDT - 2 years ago

ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update

Arthur_PL Oct. 24 at 2:15 PM

$ALXO so... we got it!

0 · Reply

the_cha_rtist Oct. 24 at 1:28 AM

$ALXO technically speaking $7 is the target

1 · Reply

Thestocktraderhubzee Oct. 23 at 5:06 PM

$ALXO ALX Oncology Presents Preclinical Data And Trial Design For Ongoing Phase 1 Clinical Trial For ADC Candidate, ALX2004, In Two Poster Presentations At 2025 AACR-NCI-EORTC Conference

0 · Reply

S2K_TP Oct. 23 at 4:50 PM

$ALXO 52%⬆️ 2 break on watch next 🚨

0 · Reply

Groin Oct. 23 at 3:44 PM

$ALXO been waiting too long for this cup

1 · Reply

Groin Oct. 23 at 3:21 PM

$ALXO We're back baby !

0 · Reply

jjrrjjrr Oct. 23 at 3:16 PM

$ALXO 🤫🤫

0 · Reply

StarLord13 Oct. 20 at 4:32 PM

$ALXO Need to break out of this downward channel.

0 · Reply

StarLord13 Oct. 16 at 8:06 PM

$ALXO This held up quite well considering where the rest of the market landed today.

1 · Reply

MakingMoneyHere Oct. 16 at 4:06 PM

$ALXO We need bulls here 😤

0 · Reply

StarLord13 Oct. 14 at 8:09 PM

$ALXO Got over FOMC fear just for a Trump tweet to tank this eod ffs 🤦‍♂️

0 · Reply

StarLord13 Oct. 14 at 3:25 PM

$ALXO Picked up another thousand shares here. Got one more buy order left in me if it falls any further, but I’m getting quite content with the amount of shares I’m currently holding.

1 · Reply

MakingMoneyHere Oct. 13 at 5:33 PM

$ALXO Okey, be ready for 4, 5 dollar's 💸

0 · Reply

maplelakeduckslayer Oct. 13 at 3:19 PM

$ALXO added some of what I sold back today 1.57 but given overall market environment not getting too aggressive yet

0 · Reply

MakingMoneyHere Oct. 10 at 1:53 PM

$ALXO Go up mo**er f*cker

0 · Reply

StarLord13 Oct. 8 at 10:28 PM

$ALXO Institutions have been adding 👀 https://fintel.io/so/us/alxo/millennium-management-llc

0 · Reply

superyin Oct. 8 at 8:15 PM

$TLRY as heroic as he is, I don't want our community to conflate Keith's accomplishments with our collective theory, there is a deep value to Tilray that is independent of the concept of blowing up an institutional short with consumer buying out the outstanding shares and holding, GME is more like VW, $TLRY is more like $ALXO imho

1 · Reply

MakingMoneyHere Oct. 8 at 6:04 PM

$ALXO Last 3 months

0 · Reply